The restructured agreement eliminates all milestone payments and reduces royalties owed to Genzyme to single digits. In return for the reduced future payments to Genzyme, Callisto is paying
As part of the agreement, Cilag International will pay upfront and milestone payments up to $39 million as well as ongoing royalties on commercial sales of Vivitrol in
The Phase III safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular events driven study of between 2,400 and 3,100 women exposed to LibiGel or placebo for 12
Under the terms of the agreement, Eucalyptus has acquired worldwide exclusive rights to develop and commercialize the molecule and Yissum together with Ramot, the technology transfer company of
The Phase II trial for NKTR-118 is a multi-center, placebo-controlled, dose-escalation trial (5mg, 25mg, 50mg or 100mg) that will evaluate the efficacy, safety and tolerability of NKTR-118 in
While this trial remains blinded overall, a portion of data on 210 patients was unblinded for review at interim analysis. The company’s medical consultants and external independent reviewers
AMG 623, which has completed Phase Ib studies in systemic lupus erythematosus patients, is a peptide fusion protein that binds to B-cell activating factor (BAFF). Anthera anticipates initiating
The boards of directors of both companies have approved the transaction. The purchase price is $29.5 million in cash plus the assumption of certain operating liabilities, subject to
The open-label, multi-center, dose-escalation, multi-dose Phase I clinical trial is expected to enroll up to 40 patients with advanced clear cell renal cell carcinoma (ccRCC) and is designed
The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.